X
Email:
sales@ruixibiotech.com

A-1331852,cas:1430844-80-6

6-[8-[(2-benzothiazolylamino)carbonyl]-3,4-dihydro-2(1H)-isoquinolinyl]-3-[5-methyl-1-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)-1H-pyrazol-4-yl]-2-pyridinecarboxylic acid

Catalog # Pkg Size Price(USD) Quantity Buy this product
R-XASYS-00572 25mg 410.00
- +
+ Add to cart
R-XASYS-00572 100mg 1182.00
- +
+ Add to cart

Product description

A-1331852(C38H38N6O3S,658.82) is an orally bioavailable Bcl-xL inhibitor that selectively binds Bcl-xL over Bcl-2, Mcl-1, and Bcl-W (Kis = <0.01, 6, 142, and 4 nM, respectively).1 It inhibits growth of Bcl-xL-dependent MOLT-4, but not Bcl-2-dependent RS4;11, acute lymphocytic leukemia cells in vitro (EC50s = 6 and >5,000 nM, respectively).

A-1331852,cas:1430844-80-6

Appearance N/A
Molecular Weight N/A
Purity >90%
Solubility N/A
Storage -20℃, protected from light and moisture
Transportation 4-25℃ temperature for up to 3 weeks
Stability 1 year
Document

Related Product